Navigation Links
Cell Therapeutics Announces Presentation of Interim Results from Phase 2 Tosedostat Trial in Older Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) at ASH Annual Meeting
Date:12/9/2013

SEATTLE, Dec. 10, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced promising interim results from an investigator-initiated Phase 2 clinical trial of tosedostat in combination with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). Tosedostat is a first-in-class selective inhibitor of aminopeptidases, which are required by tumor cells to provide amino acids necessary for growth and tumor cell survival. Tosedostat is administered orally and has been previously shown to induce complete remissions as monotherapy in relapsed or refractory AML. Researchers presented the findings from this combination study today for the first time at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition held December 7–10 in New Orleans, La.

"Treatment outcomes for older patients with newly diagnosed AML remain poor," said John Pagel, M.D., Ph.D., Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center; Associate Professor, Medical Oncology Division, University of Washington School of Medicine; and Principal Investigator in the tosedostat first-line AML/MDS trial. "This is the first time that tosedostat has been given in a front-line setting in combination with low intensity therapy. The complete response rates and median survival observed in previously untreated older patients with AML is promising and appears to be worthy of further clinical investigation." 

The Phase 2 trial was designed to test the efficacy of tosedostat in combination with low intensity therapy for older patients with previously untreated AML or high-risk MDS not considered candidates for standard intensive therapy. This presentation reported on the results of 26 patients (median age was 69) enrolled in t
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... --  Health 2.0 announces Bernard Tyson , CEO ... Eric Topol , Patrick Soon-Shiong , and Samsung,s President ... Annual Fall Conference this coming Sept. 21-24 in ... is set to host the very first Wearable Tech Fashion ... Consumer Tech & Wearables: Powering Healthy Lifestyles. The panel ...
(Date:7/28/2014)... Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC ... and audio webcast to discuss financial results for the second ... July 31, 2014 at 4:30 p.m. ET. ... July 31, 2014 Time: 4:30 PM ET Listen via Internet: ... A webcast replay will be available on the ...
(Date:7/28/2014)... 2014 STAAR Surgical Company (NASDAQ: ... implantable lenses and delivery systems for the eye has ... conference call with investors to July 31, 2014 at ... rescheduled the release date and conference call to enable ... Hideo Watanabe , President of STAAR Japan, who passed ...
Breaking Medicine Technology:Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 2Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 3Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014 2STAAR Surgical Moves Second Quarter Earnings Release and Conference Call One Day to July 31 2
... 11, 2012 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: ... pharmaceutical company specializing in the development, manufacturing, and marketing ... that the annual general meeting of shareholders (the "Meeting") ... 10 a.m. Beijing time. The meeting will be held ...
... 10, 2012 The " Ablation ... " analyzes and studies the major market drivers, restraints, ... the World. Browse market data tables ... Ablation Technologies Market (2011-2016) - Global Trends & Competitive ...
Cached Medicine Technology:Simcere Pharmaceutical Group Provides Notice of Annual General Meeting 2Global Ablation Technologies Market worth $12.4 Billion by 2016: MarketsandMarkets 2Global Ablation Technologies Market worth $12.4 Billion by 2016: MarketsandMarkets 3
(Date:7/29/2014)... July 29, 2014 The global market ... million by 2020, growing at an estimated CAGR of ... study by Grand View Research, Inc. Introduction of technological ... by the geriatric population, along with increase in demand ... major drivers of this market. In addition, presence of ...
(Date:7/29/2014)... The National Foundation for Infectious Diseases ... of A Silver Award winner for "Keeping the ... age six months and older to be vaccinated against ... power to enrich lives through its steady communications effort ... about the importance of vaccination. , “Congratulations ...
(Date:7/29/2014)... Riverdale Urgent Care is making community service ... presence at local events, partnerships and other initiatives, the ... a medical service for the Riverdale neighborhood. , ... of Riverdale RiverFest and South Riverdale Street Fair. Riverdale ... musicians and entertainers, arts and crafts, boat rides and ...
(Date:7/29/2014)... The Cottages Investment Group, LLC ... MeadowLands Memory Care, to break ground July 30, 2014. ... memory loss and forms of dementia, Wade T. Micoley, ... of Oconto Fall’s first assisted living facility with a ... Cottages Investment Group, LLC will license the facility as ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 In today’s world, ... difficult to get. Snoring and sleep apnea (a medical problem ... people and their bed partners of the rest they need ... of the population snores and 20 million people in the ... have been diagnosed and treated; and of those treated, many ...
Breaking Medicine News(10 mins):Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 2Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 3Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 4Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 5Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 6Health News:National Foundation for Infectious Diseases Receives Top ASAE Honors for Keeping the Nation Flu-Focused 2Health News:Riverdale Urgent Care of the Bronx, NY Puts a Face Back on Medicine 2Health News:Riverdale Urgent Care of the Bronx, NY Puts a Face Back on Medicine 3Health News:The Cottages Investment Group Announces Third Development Project, The Cottages at MeadowLands Memory Care, Oconto Falls 2Health News:The Cottages Investment Group Announces Third Development Project, The Cottages at MeadowLands Memory Care, Oconto Falls 3Health News:The Cottages Investment Group Announces Third Development Project, The Cottages at MeadowLands Memory Care, Oconto Falls 4Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... Hospira, Inc. (NYSE: HSP ), a leading global ... host a conference call to discuss its second-quarter 2009 results on ... , , The company will release its second-quarter 2009 results ... conference call. , , A live webcast of the ...
... military readiness, harms the health of soldiers and veterans, ... of Defense and Veterans Affairs, these agencies should implement ... goal of a tobacco-free military, says a new report ... phase in a ban on tobacco use in the ...
... Ormco Corporation, a subsidiary of Danaher Corporation (NYSE: ... jury verdict in its patent infringement case against Align Technology, ... to straighten teeth. The jury unanimously found that Align,s ... a patent held by Ormco. The claims at issue ...
... 26 Warner Chilcott Limited announced today that it will ... Meeting") and a Special Court-Ordered Meeting of Shareholders (the "Special ... the Company,s shareholders will be asked to vote in favor ... Company from Bermuda to Ireland. Subject to shareholder approval ...
... Calif., June 26 Align Technology, Inc. (Nasdaq: ... against Align in a lawsuit brought by Ormco Corporation (Ormco) ... for the Central District of California (District Court). Ormco alleged ... non-infringement, invalidity, as well as unenforceability of the patent. ...
... R.I., June 26 CVS Caremark (NYSE: ... been named as one of the nation,s leading corporations for innovative ... their families to make better choices about their own health and ... ) , , CVS Caremark received the ...
Cached Medicine News:Health News:DOD, VA should take stronger steps to combat tobacco use in military, veteran populations 2Health News:DOD, VA should take stronger steps to combat tobacco use in military, veteran populations 3Health News:Jury Renders Verdict for Ormco - Align's Invisalign(R) Product Infringes Ormco Patent 2Health News:Warner Chilcott to Hold 2009 Annual General Meeting of Shareholders and Special Court-Ordered Meeting of Shareholders 2Health News:Align Technology Announces Jury Verdict in Patent Litigation With Ormco Corporation 2Health News:CVS Caremark Recognized with Gold Award from National Business Group on Health for Promoting Healthy Lifestyles for Employees 2Health News:CVS Caremark Recognized with Gold Award from National Business Group on Health for Promoting Healthy Lifestyles for Employees 3
... The SleepStyle 200 series offers a ... CPAP models. The design delivers therapy ... Performance features promote results in commercial ... The strongest differentiator in the SleepStyle ...
... Lightweight II CPAP has sound absorption ... maintains consistent pressure. The backlit silicone ... settings easy, and the interface to ... is simple. This CPAP device comes ...
The SleepStyle 600 series with ThermoSmart delivers humidification with anti-rainout benefits. ThermoSmart technology offers a heated breathing tube that allows the constant delivery of optimal level...
The S7 Lightweight offers the comfort and reliability of the award-winning S7 series in a convenient, affordable device....
Medicine Products: